Lexeo Therapeutics (NASDAQ:LXEO) Upgraded by Wall Street Zen to “Hold” Rating

Wall Street Zen upgraded shares of Lexeo Therapeutics (NASDAQ:LXEO) from a sell rating to a hold rating in a report issued on Saturday.

Other research analysts also recently issued reports about the company. Weiss Ratings downgraded Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, May 1st. Chardan Capital reaffirmed a “buy” rating and set a $17.00 target price on shares of Lexeo Therapeutics in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $18.88.

Lexeo Therapeutics Trading Down 7.5%

Shares of NASDAQ:LXEO opened at $5.09 on Friday. Lexeo Therapeutics has a 12-month low of $2.51 and a 12-month high of $10.99. The company has a market capitalization of $399.67 million, a PE ratio of -3.51 and a beta of 1.52. The business has a 50 day moving average of $6.09 and a two-hundred day moving average of $7.68.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. Equities research analysts predict that Lexeo Therapeutics will post -1.2 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Richard Nolan Townsend sold 55,000 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $5.69, for a total value of $312,950.00. Following the completion of the transaction, the chief executive officer directly owned 340,106 shares of the company’s stock, valued at approximately $1,935,203.14. This represents a 13.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 68,189 shares of company stock valued at $397,156. 5.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Lexeo Therapeutics

Several large investors have recently added to or reduced their stakes in LXEO. RA Capital Management L.P. purchased a new stake in Lexeo Therapeutics in the 4th quarter valued at $49,650,000. Paradigm Biocapital Advisors LP purchased a new stake in Lexeo Therapeutics in the 4th quarter valued at $47,299,000. Balyasny Asset Management L.P. purchased a new stake in Lexeo Therapeutics in the 2nd quarter valued at $16,117,000. Avoro Capital Advisors LLC purchased a new stake in Lexeo Therapeutics in the 4th quarter valued at $32,769,000. Finally, State Street Corp grew its holdings in Lexeo Therapeutics by 485.1% in the 4th quarter. State Street Corp now owns 3,187,722 shares of the company’s stock valued at $31,654,000 after buying an additional 2,642,877 shares in the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.